662 related articles for article (PubMed ID: 30322867)
21. Alterations in
Oehl K; Vrugt B; Wagner U; Kirschner MB; Meerang M; Weder W; Felley-Bosco E; Wollscheid B; Bankov K; Demes MC; Opitz I; Wild PJ
Clin Cancer Res; 2021 Apr; 27(8):2277-2291. PubMed ID: 33547197
[TBL] [Abstract][Full Text] [Related]
22. Morphological difference between pleural mesothelioma cells in effusion smears with either BAP1 loss or 9p21 homozygous deletion and reactive mesothelial cells without the gene alterations.
Matsumoto S; Hamasaki M; Kinoshita Y; Kamei T; Kawahara K; Nabeshima K
Pathol Int; 2019 Nov; 69(11):637-645. PubMed ID: 31580004
[TBL] [Abstract][Full Text] [Related]
23. The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
Giroux Leprieur E; Hirata T; Mo M; Chen Z; Okamoto J; Clement G; Li H; Wislez M; Jablons DM; He B
Lung Cancer; 2014 Sep; 85(3):465-71. PubMed ID: 25023662
[TBL] [Abstract][Full Text] [Related]
24. Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component.
Matsumoto S; Nabeshima K; Hamasaki M; Shibuta T; Umemura T
Med Oncol; 2014 Dec; 31(12):303. PubMed ID: 25358615
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.
Quispel-Janssen JM; Badhai J; Schunselaar L; Price S; Brammeld J; Iorio F; Kolluri K; Garnett M; Berns A; Baas P; McDermott U; Neefjes J; Alifrangis C
Clin Cancer Res; 2018 Jan; 24(1):84-94. PubMed ID: 29061644
[No Abstract] [Full Text] [Related]
26. Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape.
Dagogo-Jack I; Madison RW; Lennerz JK; Chen KT; Hopkins JF; Schrock AB; Ritterhouse LL; Lester A; Wharton KA; Mino-Kenudson M; Danziger N; Hung YP; Mata DA; Ross JS
JCO Precis Oncol; 2022 Jun; 6():e2100422. PubMed ID: 35704798
[TBL] [Abstract][Full Text] [Related]
27. High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.
Nasu M; Emi M; Pastorino S; Tanji M; Powers A; Luk H; Baumann F; Zhang YA; Gazdar A; Kanodia S; Tiirikainen M; Flores E; Gaudino G; Becich MJ; Pass HI; Yang H; Carbone M
J Thorac Oncol; 2015 Apr; 10(4):565-76. PubMed ID: 25658628
[TBL] [Abstract][Full Text] [Related]
28. Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.
Kalra N; Zhang J; Thomas A; Xi L; Cheung M; Talarchek J; Burkett S; Tsokos MG; Chen Y; Raffeld M; Miettinen M; Pastan I; Testa JR; Hassan R
BMC Cancer; 2015 May; 15():376. PubMed ID: 25952750
[TBL] [Abstract][Full Text] [Related]
29. Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array.
Chirac P; Maillet D; Leprêtre F; Isaac S; Glehen O; Figeac M; Villeneuve L; Péron J; Gibson F; Galateau-Sallé F; Gilly FN; Brevet M
Hum Pathol; 2016 Sep; 55():72-82. PubMed ID: 27184482
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
Laszlo V; Hoda MA; Garay T; Pirker C; Ghanim B; Klikovits T; Dong YW; Rozsas A; Kenessey I; Szirtes I; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zöchbauer-Müller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Dome B; Hegedus B
J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651
[TBL] [Abstract][Full Text] [Related]
31. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guo G; Chmielecki J; Goparaju C; Heguy A; Dolgalev I; Carbone M; Seepo S; Meyerson M; Pass HI
Cancer Res; 2015 Jan; 75(2):264-9. PubMed ID: 25488749
[TBL] [Abstract][Full Text] [Related]
32. Association Between Clinicopathological Factors and Genomic Abnormalities Detected by FISH Analysis in Epithelioid Diffuse Malignant Pleural Mesothelioma.
Takeda M; Kasai T; Hatakeyama K; Nakai T; Itami H; Uchiyama T; IIzuka N; Maruyama H; Ohbayashi C
Int J Surg Pathol; 2017 Dec; 25(8):668-673. PubMed ID: 28673192
[TBL] [Abstract][Full Text] [Related]
33. An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation.
Cheung M; Kadariya Y; Pei J; Talarchek J; Facciolo F; Visca P; Righi L; Cozzi I; Testa JR; Ascoli V
Cancer Genet; 2015 Oct; 208(10):502-7. PubMed ID: 26364129
[TBL] [Abstract][Full Text] [Related]
34. Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Nabeshima K
Pathol Int; 2020 Sep; 70(9):671-679. PubMed ID: 32542810
[TBL] [Abstract][Full Text] [Related]
35. Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma.
Mairinger FD; Walter RF; Ting S; Vollbrecht C; Kollmeier J; Griff S; Hager T; Mairinger T; Christoph DC; Theegarten D; Schmid KW; Wohlschlaeger J
Future Oncol; 2014 May; 10(6):995-1005. PubMed ID: 24941985
[TBL] [Abstract][Full Text] [Related]
36. Molecular characterization of localized pleural mesothelioma.
Hung YP; Dong F; Dubuc AM; Dal Cin P; Bueno R; Chirieac LR
Mod Pathol; 2020 Feb; 33(2):271-280. PubMed ID: 31371807
[TBL] [Abstract][Full Text] [Related]
37. Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
Andersen M; Trapani D; Ravn J; Sørensen JB; Andersen CB; Grauslund M; Santoni-Rugiu E
Anticancer Res; 2015 Nov; 35(11):6223-9. PubMed ID: 26504055
[TBL] [Abstract][Full Text] [Related]
38. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
[TBL] [Abstract][Full Text] [Related]
39. Expression of Numb and Gli1 in malignant pleural mesothelioma and their clinical significance.
Zhang C; Kang Y; Ma R; Chen F; Chen F; Dong X
J Cancer Res Ther; 2018; 14(5):970-976. PubMed ID: 30197333
[TBL] [Abstract][Full Text] [Related]
40. Molecular Characterization of Malignant Mesothelioma: Time for New Targets?
Aggarwal C; Albelda SM
Cancer Discov; 2018 Dec; 8(12):1508-1510. PubMed ID: 30510013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
